Far-Red Light Activatable, Multifunctional Prodrug for Fluorescence Optical Imaging and Combinational Treatment

Bio, Moses; Rajaputra, Pallavi; Nkepang, Gregory; You, Youngjae

doi:10.1021/jm5000722

Cited by 80 publications

(95 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prodrug 88a was developed to achieve multifunction activity, including the release of drug, fluorescence imaging, and photodynamic therapy. 234 The compound 88b was designed as a pseudo-prodrug to assess the effects of photodynamic therapy and confirm the potential application of the prodrug 88a in vivo. The time-dependent distribution of 88a was investigated using Balb/c mice with SC tumors (colon-26 cells, 4-6 mm in length).…”

Section: à2mentioning

confidence: 99%

Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy

et al. 2017

View full text Add to dashboard Cite

Surgical resection of solid tumors is currently the gold standard and preferred therapeutic strategy for cancer. Chemotherapy drugs also make a significant contribution by inhibiting the rapid growth of tumor cells and these two approaches are often combined to enhance treatment efficacy. However, surgery and chemotherapy inevitably lead to severe side effects and high systemic toxicity, which in turn results in poor prognosis. Precision medicine has promoted the development of treatment modalities that are developed to specifically target and kill tumor cells. Advances in in vivo medical imaging for visualizing tumor lesions can aid diagnosis, facilitate surgical resection, investigate therapeutic efficacy, and improve prognosis. In particular, the modality of fluorescence imaging has high specificity and sensitivity and has been utilized for medical imaging. Therefore, there are great opportunities for chemists and physicians to conceive, synthesize, and exploit new chemical probes that can image tumors and release chemotherapy drugs in vivo. This review focuses on small molecular ligand-targeted fluorescent imaging probes and fluorescent theranostics, including their design strategies and applications in clinical tumor treatment. The progress in chemical probes described here suggests that fluorescence imaging is a vital and rapidly developing field for interventional surgical imaging, as well as tumor diagnosis and therapy.

show abstract

Section: à2mentioning

confidence: 99%

Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Based on the presence of CD33 on acute myeloid leukemia (AML) blasts and some leukemic stem cells, gemtuzumab ozogamicin (GO), an anti-CD33 antibody carrying the cytotoxic calicheamicin has been developed to treat AML [231]. Several other markers including CD44 [232], IL-3RA or CD123 [233], the immunoglobulin mucin TIM-3 [234] and folate receptor beta (FRβ) [235], have been extensively explored to specifically target leukemic stem cells in human AML.…”

Section: Novel Strategies For Cancer Targeted Deliverymentioning

confidence: 99%

“…[229]. Other derivatives of colchicine [230], estradiol [231], combretastatin [232, 233] and phenstatin [234] have been synthesized and have shown better efficacy relative to parent drug.…”

Section: Prodrug Approach: Analog / Chemical Conjugation For Cancementioning

confidence: 99%

Novel delivery approaches for cancer therapeutics

Mitra

Agrahari

Mandal

et al. 2015

Journal of Controlled Release

138

View full text Add to dashboard Cite

Currently, a majority of cancer treatment strategies are based on the removal of tumor mass mainly by surgery. Chemical and physical treatments such as chemo- and radiotherapies have also made a major contribution in inhibiting rapid growth of malignant cells. Furthermore, these approaches are often combined to enhance therapeutic indices. It is widely known that surgery, chemo- and radiotherapy also inhibit normal cells growth. In addition, these treatment modalities are associated with severe side effects and high toxicity which in turn lead to low quality of life. This review encompasses novel strategies for more effective chemotherapeutic delivery aiming to generate better prognosis. Currently, cancer treatment is a highly dynamic field and significant advances are being made in the development of novel cancer treatment strategies. In contrast to conventional cancer therapeutics, novel approaches such as ligand or receptor based targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, have added new modalities for cancer treatment. These approaches have led to selective detection of malignant cells leading to their eradication with minimal side effects. Lowering, multi-drug resistance and involving influx transportation in targeted drug delivery to cancer cells can also contribute significantly in the therapeutic interventions in cancer.

show abstract

“…25,26 For example, the sensitized generation of 1 O 2 ( 1 Δ g ) has been used with labile ethene linkers for photorelease reactions. We 27,28 and others 29–31 have published papers devoted to 1 O 2 -based drug release and a book chapter has also appeared. 32 Singlet oxygen is a potentially therapeutic species and is photogenerated by PAHs, 33,34 chlorins, 35,36 porphyrins and phthalocyanines, and their fluorinated analogs.…”

Section: Introductionmentioning

confidence: 99%

Photoactive Fluoropolymer Surfaces That Release Sensitizer Drug Molecules

et al. 2015

View full text Add to dashboard Cite

We describe a physical-organic study of two fluoropolymers bearing a photoreleasable PEGylated photosensitizer which generates 1O2(1Δg) [chlorin e6 methoxy tri(ethylene glycol) triester]. The surfaces are Teflon/polyvinylalcohol (PVA) nanocomposite and fluorinated silica. The relative efficiency of these surfaces to photorelease the PEGylated sensitizer [shown previously to be phototoxic to ovarian cancer cells (Kimani, S. et al J. Org. Chem 2012, 77, 10638)] was slightly higher for the nanocomposite. In the presence of red light and O2, 1O2 is formed, which cleaves an ethene linkage to liberate the sensitizer in 68–92% yields. The fluoropolymers were designed to deal with multiple problems. Namely, their success relied not only high O2 solubility and drug repellency, but that the C−F bonds physically quench little 1O2 for its productive use away from the surface. The results obtained here indicate that Teflon-like surfaces have potential uses of delivering sensitizer and singlet oxygen for applications in tissue repair and photodynamic therapy (PDT).

show abstract

Far-Red Light Activatable, Multifunctional Prodrug for Fluorescence Optical Imaging and Combinational Treatment

Cited by 80 publications

References 27 publications

Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy

Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy

Novel delivery approaches for cancer therapeutics

Photoactive Fluoropolymer Surfaces That Release Sensitizer Drug Molecules

Contact Info

Product

Resources

About